Trial Profile
Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2015
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Traveller's diarrhoea
- Focus Therapeutic Use
- 07 Oct 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Oct 2009 Planned end date changed from 1 Sep 2010 to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record